David P. Brooks

5.5k total citations
178 papers, 4.0k citations indexed

About

David P. Brooks is a scholar working on Social Psychology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, David P. Brooks has authored 178 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Social Psychology, 54 papers in Molecular Biology and 41 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in David P. Brooks's work include Neuroendocrine regulation and behavior (57 papers), Electrolyte and hormonal disorders (31 papers) and Renin-Angiotensin System Studies (30 papers). David P. Brooks is often cited by papers focused on Neuroendocrine regulation and behavior (57 papers), Electrolyte and hormonal disorders (31 papers) and Renin-Angiotensin System Studies (30 papers). David P. Brooks collaborates with scholars based in United States, United Kingdom and Netherlands. David P. Brooks's co-authors include Leonard Share, Joan T. Crofton, Richard M. Edwards, Eliot H. Ohlstein, Mark Pullen, Robert Ruffolo, Ponnal Nambi, Lisa C. Contino, Nicholas J. Laping and P Nambi and has published in prestigious journals such as The Lancet, Circulation and The Journal of Physiology.

In The Last Decade

David P. Brooks

176 papers receiving 3.8k citations

Peers

Countries citing papers authored by David P. Brooks

Since Specialization

Citations

This map shows the geographic impact of David P. Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Brooks more than expected).

Fields of papers citing papers by David P. Brooks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Brooks. The network helps show where David P. Brooks may publish in the future.

Co-authorship network of co-authors of David P. Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of David P. Brooks. A scholar is included among the top collaborators of David P. Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David P. Brooks. David P. Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X) 2025 ·BMJ Open ·Michael E. Weinblatt, Peter C. Taylor, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David P. Brooks, Paula Curtis, Anubha Gupta, R. Nijhawan, (unknown), Katey J. Rayner, (unknown), (unknown), Millie Wang, (unknown), Roy Fleischmann	1
2	Carvedilol Prevents and Reverses Hypertrophy-Induced Cardiac Dysfunction 2007 ·Pharmacology ·Frank C. Barone, Robert N. Willette, Allen H. Nelson, Eliot H. Ohlstein, David P. Brooks, Robert W. Coatney	13
3	Antioxidant activity of carvedilol in cardiovascular disease 2007 ·Journal of Hypertension ·Paresh Dandona, Husam Ghanim, David P. Brooks	139
4	Okadaic acid stimulates caspase-like activities and induces apoptosis of cultured rat mesangial cells 2004 ·Molecular and Cellular Biochemistry ·Narayanan Parameswaran, (unknown), David P. Brooks, Ponnal Nambi	9
5	Effect of Endothelin on Bladder Contraction: Potential Role in Bladder Hyperactivity 2003 ·Pharmacology ·Timothy D. Westfall, Gerald P. McCafferty, Mark Pullen, (unknown), Marianne Eybye, M Jugus, (unknown), J. Paul Hieble, David P. Brooks	12
6	The Angiotensin Type 1 Receptor Antagonist, Eprosartan, Attenuates the Progression of Renal Disease in Spontaneously Hypertensive Stroke-Prone Rats with Accelerated Hypertension 2002 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Frank C. Barone, Wallace G. Campbell, Allen H. Nelson, Lisa C. Contino, Mark Pullen, Eugene T. Grygielko, Richard M. Edwards, Nicholas J. Laping, David P. Brooks	15
7	Rapid Isolation of Tissue-Specific Genes from Rat Kidney 2001 ·Nephron Experimental Nephrology ·Erding Hu, Zunxuan Chen, Todd A. Fredrickson, Nigel K. Spurr, (unknown), Matthew Sims, (unknown), Wendy S. Halsey, Stephanie Van Horn, (unknown), Ganesh M. Sathe, David P. Brooks	5
8	Parathyroid Hormone-1 Receptor Down-Regulation in Kidneys from Rats with Chronic Renal Failure 2001 ·Pharmacology ·Richard M. Edwards, Lisa C. Contino, Miklos Gellai, David P. Brooks	4
9	SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells 1999 ·European Journal of Pharmacology ·Narayanan Parameswaran, W. S. Spielman, David P. Brooks, Ponnal Nambi	22
10	Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data 1999 ·American Heart Journal ·David P. Brooks, Eliot H. Ohlstein, Robert Ruffolo	26
11	Involvement of Nitric Oxide Synthase in Proteinuria Associated with Chronic Renal Disease in Rats 1998 ·Pharmacology ·David P. Brooks, Lisa C. Contino	6
12	Blockade of Radiocontrast-lnduced Nephrotoxicity by the Endothelin Receptor Antagonist, SB 209670 1996 ·The Nephron journals/Nephron journals ·David P. Brooks, (unknown)	23
13	Identification and Function of Putative ETB Receptor Subtypes in the Dog Kidney 1995 ·Journal of Cardiovascular Pharmacology ·David P. Brooks, (unknown), Mark Pullen, Miklos Gellai, Ponnal Nambi	22
14	Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist 1995 ·European Journal of Pharmacology ·Nambi Aiyar, (unknown), Lynne M. Vickery‐Clark, Eliot H. Ohlstein, Miklos Gellai, Todd A. Fredrickson, David P. Brooks, Joseph Weinstock, Edwin F. Weidley, Richard M. Edwards	13
15	Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. 1994 ·Journal of Pharmacology and Experimental Therapeutics ·David P. Brooks, (unknown), M. Gellai, P Nambi, Eliot H. Ohlstein, J. D. ELLIOTT, John G. Gleason, R R Ruffolo	37
16	Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number 1991 ·European Journal of Pharmacology ·David P. Brooks, Eliot H. Ohlstein, (unknown), Barbara L. Storer, Mark Pullen, Madelyn M. Caltabiano, P Nambi	30
17	Increased endothelin excretion in rats with renal failure induced by partial nephrectomy 1991 ·British Journal of Pharmacology ·David P. Brooks, Lisa C. Contino, Barbara L. Storer, Eliot H. Ohlstein	37
18	Effect of fenoldopam in dogs with spontaneous renal insufficiency 1990 ·European Journal of Pharmacology ·David P. Brooks, Robin S. Goldstein, Paul F. Koster, (unknown), (unknown), (unknown), (unknown)	13
19	Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements 1989 ·European Journal of Pharmacology ·David P. Brooks, Paul F. Koster, Christine R. Albrightson, William F. Huffman, M. Lane Moore, F L Stassen, Dulcie B. Schmidt, Lewis B. Kinter	7
20	SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). 1988 ·PubMed ·David P. Brooks, Paul F. Koster, C R Albrightson-Winslow, F L Stassen, William F. Huffman, Lewis B. Kinter	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact